Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results

Data Visualizations

Phase Distribution

3Total
P 2 (3)

Trial Status

Active Not Recruiting2
Recruiting2

Clinical Trials (4)

Showing 4 of 4 trials
NCT07140679Phase 2Recruiting

Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer

NCT03516942Active Not Recruiting

Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment

NCT05710406Phase 2Active Not Recruiting

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

NCT07595874Phase 2Recruiting

Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3

Showing all 4 trials

Research Network

Activity Timeline